[HTML] sciencedirect.com

[HTML][HTML] Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

R Hamanaka, T Shinohara, S Yano… - … et Biophysica Acta (BBA …, 2008 - Elsevier
Active-site-specific chaperone therapy for Fabry disease is a genotype-specific therapy
using a competitive inhibitor, 1-deoxygalactonojirimycin (DGJ). To elucidate the mechanism …
被引用次数：35 相关文章

Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

R Hamanaka, T Shinohara, S Yano… - BBA-Molecular Basis of …, 2008 - infona.pl
Active-site-specific chaperone therapy for Fabry disease is a genotype-specific therapy
using a competitive inhibitor, 1-deoxygalactonojirimycin (DGJ). To elucidate the mechanism …

[引用][C] Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

R Hamanaka, T Shinohara, S Yano… - … et Biophysica Acta …, 2008 - cir.nii.ac.jp
Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin
leads to trafficking to lysosomes | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Rescue of mutant [alpha]-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

R Hamanaka, T Shinohara, S Yano… - … et Biophysica Acta …, 2008 - hero.epa.gov
Active-site-specific chaperone therapy for Fabry disease is a genotype-specific therapy
using a competitive inhibitor, 1-deoxygalactonojirimycin (DGJ). To elucidate the mechanism …

Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

R Hamanaka, T Shinohara, S Yano… - … et biophysica acta, 2008 - pubmed.ncbi.nlm.nih.gov
Active-site-specific chaperone therapy for Fabry disease is a genotype-specific therapy
using a competitive inhibitor, 1-deoxygalactonojirimycin (DGJ). To elucidate the mechanism …
[PDF] core.ac.uk

[PDF][PDF] Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

JQ Fan, K Kawasaki, M Watanabe, S Ishii - Biochimica et Biophysica …, 1782 - core.ac.uk
Active-site-specific chaperone therapy for Fabry disease is a genotype-specific therapy
using a competitive inhibitor, 1-deoxygalactonojirimycin (DGJ). To elucidate the mechanism …
[PDF] oita-u.ac.jp

[PDF][PDF] Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

JQ Fan, K Kawasaki, M Watanabe… - Biochimica et Biophysica …, 1782 - med.oita-u.ac.jp
Active-site-specific chaperone therapy for Fabry disease is a genotype-specific therapy
using a competitive inhibitor, 1-deoxygalactonojirimycin (DGJ). To elucidate the mechanism …
[PDF] hal.science

[PDF][PDF] Rescue of mutant α-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

R Hamanaka, T Shinohara, S Yano… - … et Biophysica Acta …, 2008 - hal.science
Active-site-specific chaperone therapy for Fabry disease is a genotype-specific therapy
using a competitive inhibitor, 1-deoxygalactonojirimycin (DGJ). To elucidate the mechanism …

Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes.

R Hamanaka, T Shinohara, S Yano… - … et Biophysica Acta, 2008 - europepmc.org
Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin
leads to trafficking to lysosomes. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

[引用][C] Rescue of mutant a-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes

R HAMANAKA - Biochim. Biophys, Acta, 2008 - cir.nii.ac.jp
Rescue of mutant a-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin
leads to trafficking to lysosomes | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …